Safety of TKIs in Treatment of Differentiated Thyroid Cancer
Warren C. Swegal, MD, discusses the safety and tolerability of tyrosine kinase inhibitors for patients with radioactive iodine–refractory differentiated thyroid cancer.
Growing Role of Cabozantinib Therapy in Differentiated Thyroid Cancer
Warren C. Swegal, MD, discusses the role of cabozantinib (Cabometyx) for patients with radioactive iodine (RAI)–refractory differentiated thyroid cancer (DTC).
The Role of Lenvatinib in Differentiated Thyroid Cancer Treatment
Warren Swegal, MD, explains how lenvatinib in currently used in the differentiated thyroid cancer landscape.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
2 Commerce Drive Cranbury, NJ 08512